Table 4 Dose of midazolam according to prior medications
From: Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control
Characteristics | Induction dose (mg) | Maintenance dose (mg/h) | Dose at time of death (mg/h) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Median (range) | Mean (sd) | p-value | N | Median (range) | Mean (sd) | p-value | N | Median (range) | Mean (sd) | p-value | |||||||
Prior exposure to midazolam | ||||||||||||||||||
No (N = 17) | 8 | 1.5 | (0.5–3.0) | 1.6 | (1.1) | 0.004 | 17 | 0.4 | (0.2–1.5) | 0.5 | (0.4) | < 0.001 | 16 | 1.0 | (0.2–8.0) | 1.8 | (2.0) | 0.003 |
Yes (N = 37) | 18 | 3.8 | (1.0–10.0) | 4.9 | (3.2) | 37 | 1.5 | (0.5–7.0) | 1.9 | (1.6) | 37 | 3.0 | (0.6–24) | 4.4 | (4.9) | |||
Prior exposure to strong opioids | ||||||||||||||||||
No (N = 7) | 4 | 2.0 | (1.0–3.0) | 2.0 | (0.8) | 0.22 | 7 | 0.6 | (0.2–1.5) | 0.8 | (0.4) | 0.31 | 7 | 1.0 | (0.5–3.0) | 1.3 | (0.8) | 0.025 |
Yes (N = 47) | 22 | 3.0 | (0.5–10) | 4.2 | (3.3) | 47 | 1.0 | (0.2–7.0) | 1.6 | (1.6) | 46 | 2.8 | (0.2–24) | 4.0 | (4.6) | |||
Prior exposure to medications that impair alertness | ||||||||||||||||||
No (N = 33) | 15 | 3.0 | (0.5–10.0) | 3.8 | (3.2) | 0.81 | 33 | 1.0 | (0.2–7.0) | 1.4 | (1.5) | 0.46 | 33 | 2.0 | (0.2–9.0) | 2.7 | (2.4) | 0.18 |
Yes (N = 21) | 11 | 3.0 | (0.5–10.0) | 3.9 | (3.2) | 21 | 1.0 | (0.2–5.0) | 1.6 | (1.4) | 20 | 2.8 | (0.5–24) | 5.1 | (6.3) | |||